Patients
bone marrow transplantation
immunosuppressed
dose
cyclophosphamide
CYA
patient's weight
high doses
CYA
cardiotoxicity
risk factors
development
cardiotoxicity
chemotherapeutic agent
toxicity
dose
retrospectively
calculated
dose
CYA
patients
transplanted
institution
incidence
CYA
cardiotoxicity
correlated
dose
patients
CYA
days
preparation
marrow grafting
transplants
aplastic anemia
Wiskott-Aldrich syndrome
immunodeficiency syndrome
patients
symptoms
signs
consistent with
CYA
cardiotoxicity
doses
CYA
patients
died
congestive heart failure
dose
CYA
body surface area
calculated
patients
patients
groups
daily
CYA
dose
Group 1
CYA
Group 2
CYA
Cardiotoxicity
CYA
patients
Group 1
patients
Group 2
Congestive heart failure
death
patients
Group 1 v 6/52
patients
Group 2
rate
engraftment
patients
groups
CYA
cardiotoxicity
CYA
dosage
body surface area
patients
aplastic anemia
immunodeficiencies
bone marrow grafting
CYA
dose
days
incidence
cardiotoxicity
patients
CYA
dosage
weight
study
drug toxicity
dose
